Discussion
A novel gene therapy for sickle cell disease (SCD), designed to modify blood stem cells without the need to remove and transplant them back into patients, showed proof-of-concept results in humanized mice, a study found. “Comprehensive [non-human primate] studies will be required to assess safety, biodistribution [how the therapy…